Literature DB >> 32180276

Aprepitant in refractory pruritus of systemic lymphoproliferative disorders.

A Pulido-Perez1, F Carretero-Lopez2, M Bergon-Sendin1, L M Nieto-Benito1, R Romero-Jimenez3, N Dorado-Herrero4, M B Bastos-Oreiro4, R Suárez-Fernández1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32180276     DOI： 10.1111/jdv.16370

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  1 in total

1.  Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

Authors:  C Le Gall-Ianotto; R Verdet; E Nowak; L Le Roux; A Gasse; A Fiedler; D Carlhant-Kowalski; P Marcorelles; L Misery; J C Ianotto
Journal:  Trials       Date:  2021-12-19       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.